Results from trials investigating immunotherapy in PD-L1 positive recurrent/metastatic HNSCC demonstrated statistically significant overall survival benefit, leading to changes in standard of care treatment which now includes immune checkpoint inhibitors, either alone or in combination with chemotherapy. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.